Wei Peng Email & Phone Number

Cn

Closed deals (total size of around US$ 500mn):- Minority investment in Biosensors (B20.SG) in 2013- Minority investment in Guangwei Composites (300699) in 2013- Led the Series A and A+ financing of BeiGene (BGNE.O) in 2014 and 2015- Leveraged Buyout of Biosensors (B20.SG) and privatized the company from SGX in 2016- Buyout of Dingjian Medical in 2017 (board member) - Buyout of Changsha Changhao Hospital in 2018- Led the Series E financing of Bondent in 2020 (board member)- Led the Series E financing of Kindstar Global (9960.HK) in 2020 (board member)- Led the Series B financing of Dearer Lens in 2021 (board member)- Led the Series C+ financing of Genskey in 2021- Led the PIPE of Shining3D (830978.NQ) in 2022- Participated in the debt restructuring of HengKang Medical Group (002219) in 2022Realized exits：- Shanghai CP Guojian (688336)- BeiGene (BGNE.O)- 3S Bio (1530.HK)- Lvye Pharma (2186.HK)- Biosensors, share swap with Bluesail (002382)- Changhao Hospital, trade sale

Kowloon, Hk

- Help clients on various types of engagements, i.e. investment assessment, M&A strategy, commercial due diligence, post-merger integration/business planning, corporate/product growth strategy, pricing strategy and re-organization

Master Of Business Administration - Mba, Investment

Bachelor, Electronic Engineering, Finance